Oral immunization against HIV/AIDS with prime-boost strategies

采用初免-加强策略口服艾滋病毒/艾滋病免疫

基本信息

  • 批准号:
    7995820
  • 负责人:
  • 金额:
    $ 53.81万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2010
  • 资助国家:
    美国
  • 起止时间:
    2010-12-01 至 2015-11-30
  • 项目状态:
    已结题

项目摘要

DESCRIPTION (provided by applicant): Mucosal transmission represents the predominant mode of global HIV acquisition. Oral transmission is rare. However, it does occur, in adults and in infants, with the latter occurring most likely through ingestion of milk from HIV-infected mothers. If an effective vaccine can be formulated for orally delivery, it is likely to protect not only against oral and other mucosal transmission, but also enhance vaccine access through its ease of administration, thus providing a cost-effective preventive approach against HIV/AIDS. Over the past two decades, our lab has demonstrated the feasibility of parenteral immunization with a poxvirus prime/protein boost strategy, resulting in complete or partial protection against mucosal SIV or SHIV challenge in macaques. In this application, we propose to extend these findings and to leverage recent developments in natural Toll-like receptor (TLR) ligands and oral formulation technologies to explore the possibility of adapting this immunization approach for oral vaccination against HIV/AIDS. The overall hypothesis we propose is that effective oral delivery of poxvirus and protein vaccines in a prime-boost immunization strategy will generate greater oral and mucosal responses than parenteral immunizations, resulting in protection against mucosal challenge. The Specific Aims are: (1) To evaluate the safety and immunogenicity of oral delivery of a replication competent, attenuated poxvirus vaccine; (2) To evaluate the safety and immunogenicity of protein vaccines adjuvanted with a natural TLR ligand and formulated for oral delivery; (3) To compare the immunogenicity of poxvirus prime and protein boost approach in different oral and parenteral delivery regimens; (4) To evaluate the protective efficacy of oral delivered prime/boost vaccines against mucosal challenge in non-human primate models. Results from these studies are likely to help elucidate the protective mechanisms against HIV/AIDS and inform the clinical development of the poxvirus prime/protein boost immunization concept. PUBLIC HEALTH RELEVANCE: Most HIV infections result from mucosal transmission, including transmissions through the oral mucosa. Orally delivered vaccines are easy to administer and are likely to induce immunity at mucosal sites. In this proposal, we will examine oral formulations and delivery of a prime-boost vaccination strategy for its potential to generate protective immunity in macaque models.
描述(申请人提供):粘膜传播是全球艾滋病毒感染的主要方式。经口传播是罕见的。然而,它确实发生在成人和婴儿身上,后者很可能是通过摄入感染艾滋病毒的母亲的牛奶而发生的。如果能够配制一种有效的口服疫苗,它不仅可能预防口腔和其他粘膜传播,而且还可以通过其易于接种而增加疫苗的获得,从而提供一种具有成本效益的艾滋病毒/艾滋病预防方法。在过去的二十年里,我们的实验室已经证明了使用痘病毒主/蛋白增强策略进行肠外免疫的可行性,从而对猕猴的黏膜SIV或SIV攻击产生完全或部分保护。在这一应用中,我们建议扩展这些发现,并利用天然Toll样受体(TLR)配体和口服制剂技术的最新发展来探索将这种免疫方法应用于口服艾滋病毒/艾滋病疫苗的可能性。我们提出的总体假设是,在主要增强免疫策略中,有效的口服痘病毒和蛋白质疫苗将比非肠道免疫产生更大的口腔和粘膜反应,从而保护免受粘膜攻击。具体目的是:(1)评估具有复制能力的减毒痘病毒疫苗口服给药的安全性和免疫原性;(2)评估以天然TLR配基为佐剂的蛋白质疫苗口服给药的安全性和免疫原性;(3)比较不同口服和非肠道给药方案中痘病毒初级和蛋白质增强途径的免疫原性;(4)在非人类灵长类动物模型中评价口服优质/增强疫苗对黏膜攻击的保护作用。这些研究的结果可能有助于阐明对艾滋病毒/艾滋病的保护机制,并为痘病毒初级/蛋白质增强免疫概念的临床发展提供信息。 公共卫生相关性:大多数艾滋病毒感染是由粘膜传播引起的,包括通过口腔粘膜传播。口服疫苗易于接种,并可能在粘膜部位诱导免疫。在这项提案中,我们将检查口服配方和主要增强疫苗接种策略的交付,以确定其在猕猴模型中产生保护性免疫的潜力。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Shiu-Lok Hu其他文献

Shiu-Lok Hu的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Shiu-Lok Hu', 18)}}的其他基金

VIRUS-LIKE PARTICLES WITH STABILIZED TRIMERIC ENVELOPE FOR PRIME BOOST IMMUNIZATION
具有稳定三聚体包膜的病毒样颗粒,用于初免加强免疫
  • 批准号:
    9530535
  • 财政年份:
    2017
  • 资助金额:
    $ 53.81万
  • 项目类别:
PROTECTIVE EFFICACY OF GLYCAN-MODIFIED ENV VACCINE
聚糖修饰的 ENV 疫苗的保护作用
  • 批准号:
    8357597
  • 财政年份:
    2011
  • 资助金额:
    $ 53.81万
  • 项目类别:
Recombinant Protein Immunogens
重组蛋白免疫原
  • 批准号:
    8327071
  • 财政年份:
    2011
  • 资助金额:
    $ 53.81万
  • 项目类别:
IMMUNOPATHOGENESIS OF CLADE C SHIV-1157IPD3N4 IN M NEMESTRINA
M Nemestrina 中 C 进化枝 SHIV-1157IPD3N4 的免疫发病机制
  • 批准号:
    8357596
  • 财政年份:
    2011
  • 资助金额:
    $ 53.81万
  • 项目类别:
INFECTIVITY OF HSIV-VIF CHIMERA IN PIGTAILED MACAQUES
HSIV-VIF 嵌合体在斑尾猕猴中的感染性
  • 批准号:
    8357599
  • 财政年份:
    2011
  • 资助金额:
    $ 53.81万
  • 项目类别:
COMBINED APPROACH TO BROADLY PROTECTIVE AIDS VACCINES: PROJECT 4
广泛保护性艾滋病疫苗的综合方法:项目 4
  • 批准号:
    8357598
  • 财政年份:
    2011
  • 资助金额:
    $ 53.81万
  • 项目类别:
Nonhuman Primate Core
非人类灵长类核心
  • 批准号:
    8202348
  • 财政年份:
    2011
  • 资助金额:
    $ 53.81万
  • 项目类别:
INFECTIVITY OF HSIV-VIF CHIMERA IN NEWBORN PIGTAILED MACAQUES
HSIV-VIF 嵌合体在新生短尾猴中的感染性
  • 批准号:
    8357619
  • 财政年份:
    2011
  • 资助金额:
    $ 53.81万
  • 项目类别:
INTRARECTAL TITRATION OF SHIV 162P4 STOCK
SHIV 162P4 库存的直肠内滴定
  • 批准号:
    8357586
  • 财政年份:
    2011
  • 资助金额:
    $ 53.81万
  • 项目类别:
ORIGIN AND EVOLUTION OF HIV-1 DRUG RESISTANCE
HIV-1 耐药性的起源和演变
  • 批准号:
    8357636
  • 财政年份:
    2011
  • 资助金额:
    $ 53.81万
  • 项目类别:

相似海外基金

Co-designing a lifestyle, stop-vaping intervention for ex-smoking, adult vapers (CLOVER study)
为戒烟的成年电子烟使用者共同设计生活方式、戒烟干预措施(CLOVER 研究)
  • 批准号:
    MR/Z503605/1
  • 财政年份:
    2024
  • 资助金额:
    $ 53.81万
  • 项目类别:
    Research Grant
Early Life Antecedents Predicting Adult Daily Affective Reactivity to Stress
早期生活经历预测成人对压力的日常情感反应
  • 批准号:
    2336167
  • 财政年份:
    2024
  • 资助金额:
    $ 53.81万
  • 项目类别:
    Standard Grant
RAPID: Affective Mechanisms of Adjustment in Diverse Emerging Adult Student Communities Before, During, and Beyond the COVID-19 Pandemic
RAPID:COVID-19 大流行之前、期间和之后不同新兴成人学生社区的情感调整机制
  • 批准号:
    2402691
  • 财政年份:
    2024
  • 资助金额:
    $ 53.81万
  • 项目类别:
    Standard Grant
Migrant Youth and the Sociolegal Construction of Child and Adult Categories
流动青年与儿童和成人类别的社会法律建构
  • 批准号:
    2341428
  • 财政年份:
    2024
  • 资助金额:
    $ 53.81万
  • 项目类别:
    Standard Grant
Elucidation of Adult Newt Cells Regulating the ZRS enhancer during Limb Regeneration
阐明成体蝾螈细胞在肢体再生过程中调节 ZRS 增强子
  • 批准号:
    24K12150
  • 财政年份:
    2024
  • 资助金额:
    $ 53.81万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Understanding how platelets mediate new neuron formation in the adult brain
了解血小板如何介导成人大脑中新神经元的形成
  • 批准号:
    DE240100561
  • 财政年份:
    2024
  • 资助金额:
    $ 53.81万
  • 项目类别:
    Discovery Early Career Researcher Award
Laboratory testing and development of a new adult ankle splint
新型成人踝关节夹板的实验室测试和开发
  • 批准号:
    10065645
  • 财政年份:
    2023
  • 资助金额:
    $ 53.81万
  • 项目类别:
    Collaborative R&D
Usefulness of a question prompt sheet for onco-fertility in adolescent and young adult patients under 25 years old.
问题提示表对于 25 岁以下青少年和年轻成年患者的肿瘤生育力的有用性。
  • 批准号:
    23K09542
  • 财政年份:
    2023
  • 资助金额:
    $ 53.81万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Identification of new specific molecules associated with right ventricular dysfunction in adult patients with congenital heart disease
鉴定与成年先天性心脏病患者右心室功能障碍相关的新特异性分子
  • 批准号:
    23K07552
  • 财政年份:
    2023
  • 资助金额:
    $ 53.81万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Issue identifications and model developments in transitional care for patients with adult congenital heart disease.
成人先天性心脏病患者过渡护理的问题识别和模型开发。
  • 批准号:
    23K07559
  • 财政年份:
    2023
  • 资助金额:
    $ 53.81万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了